NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…
Check Out the Wellness Pavilion at the 2019 ACR/ARP Annual Meeting
With massage chairs, creative spaces and therapy dogs, the Wellness Pavilion will offer this year’s Annual Meeting attendees respite from the busy conference atmosphere…
Race May Not Be a Risk Factor for Giant Cell Arteritis
Past research has identified being of Northern European descent as a risk factor, among others such as age, sex and HLA DRB1, for developing giant cell arteritis (GCA). But new research casts doubts on this idea, finding that rates of biopsy proven GCA may not differ by race…
Using RISE Data in Research
The ACR’s RISE registry offers answers on real-world experience to researchers.
Annual Meeting Preview: Maximizing Reimbursement Under MACRA, MIPS & APMs
A session at the 2019 ACR/ARP Annual Meeting will help rheumatologists navigate current payment systems and identify resources to ensure appropriate reimbursement for complex care.
ACR Leads Coalition Opposing Cigna’s Elimination of Consultation Codes
In a letter co-signed by other Cognitive Specialty Coalition organizations, the ACR is requesting at least a one-year delay to better coordinate payer changes with recent federal initiatives.
UnitedHealthcare Delays Policy Changes Affecting Physician-Administered Treatments
Changes announced at the beginning of October have now been delayed for Actemra, Benlysta, Cimzia, Orencia and Simponi Aria, but changes to the Stelara policy remain in effect.
Not Yet Using RISE? Learn Why You Should at the Annual Meeting
Get your questions about RISE answered—and register to join—on site at the 2019 ACR/ARP Annual Meeting.
Ethics Forum: What Are Conflicts of Interest?
Results from an ethics survey presented to attendees at the 2018 ACR/ARHP Annual Meeting highlight the complexities and challenges of assessing potential conflicts of interest.
Trump Administration Proposes Changes to Healthcare Anti-Kickback Rules
(Reuters)—The Trump administration has proposed changes to federal anti-kickback provisions that restrict the kinds of patient referrals doctors can make, saying it will improve healthcare coordination and foster payments based on the quality of care. The plan will change how the U.S. Department of Health and Human Services (HHS) enforces the Physician Self Referral Law,…
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 310
- Next Page »